WILLIAM MICHAEL SCOTT, NP
Nursing at Pickett Rd, Durham, NC

8088587, Jan 3, 2012

Mar 6, 2006

11/885336

Jonathan L. Haines - Nashville TN, US
Eric Postel - Durham NC, US
Anita Agarwal - Nashville TN, US
Michael A. Hauser - Durham NC, US
Silke Schmidt - Durham NC, US
William K. Scott - Durham NC, US

Vanderbilt University - Nashville TN
Duke University - Durham NC

G01N 31/00, G01N 33/53

435 71, 435 4, 4352879, 436501, 436518, 436525, 436529, 436535, 436809, 530300, 530350, 422 50

Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in the elderly whose etiology remains largely unknown. Previous studies identified chromosome 1q32 as harboring a susceptibility locus for AMD, but it was not identified. We identified a strongly associated haplotype in two independent data sets. DNA sequencing of the complement factor II gene (CFII) within this haplotype revealed a coding variant, Y402II, that significantly increases the risk for AMD with odds ratios between 2. 45 and 5. 57. This identifies Complement factor II as involved in pathogenesis of AMD. This single variant alone is so common that it likely explains 43 percent of AMD in older adults. In addition, we have replicated and refined previous reports implicating a coding change in LOC387715 as the second major AMD susceptibility allele. The effect of rs10490924 appears to be completely independent of the Y402H variant in the CFH gene.

2005019, Sep 1, 2005

Nov 2, 2004

10/979297

Jeffery Vance - Chapel Hill NC, US
Eden Martin - Hillsborough NC, US
William Scott - Durham NC, US
Mike Hauser - Durham NC, US

C12Q001/68

435006000

The present invention discloses methods of screening a subject for Parkinson's disease comprising detecting the presence or absence of a marker or functional polymorphism associated with a gene linked to Parkinson's disease.

2004024, Dec 9, 2004

Dec 11, 2002

10/296096

Jeffrey Vance - Chapel Hill NC, US
William Scott - Durham NC, US
Jeffrey Stajich - Hillsborough NC, US

C12Q001/68

435/006000

Methods of screening a subject for Parkinson's disease comprise detecting the presence or absence of a functional polymorphism associated with a gene linked to Parkinson's disease. The method may be used diagnostically or prognostically, including in clinical trials for the identification of treatments effective for treating patients carrying particular markers for Parkinson's disease.

2006006, Mar 30, 2006

Aug 31, 2005

11/216660

Jeffery Vance - Chapel Hill NC, US
Yi-Ju Li - Durham NC, US
Eden Martin - Hillsborough NC, US
William Scott - Durham NC, US
Michael Hauser - Durham NC, US
Jeffrey Stajich - Hillsborough NC, US
Sofia Oliveira - Lisbon, PT
Joelle van der Walt - Raleigh NC, US

C12Q 1/68

435006000

The present invention provides methods and compositions for screening a subject for Parkinson disease, for increased risk of developing Parkinson disease and/or for an earlier or later age of developing Parkinson disease, comprising detecting the presence of a genetic marker associated with Parkinson disease.

2009009, Apr 16, 2009

Oct 6, 2008

12/246068

Jeffery M. Vance - Chapel Hill NC, US
Yi-Ju Li - Durham NC, US
Eden R. Martin - Hillsborough NC, US
William K. Scott - Durham NC, US
Michael A. Hauser - Durham NC, US
Jeffrey M. Stajich - Hillsborough NC, US
Sofia Oliveira - Lisbon, PT
Joelle van der Walt - Raleigh NC, US

C12Q 1/68

435 6

The present invention provides methods and compositions for screening a subject for Parkinson disease, for increased risk of developing Parkinson disease and/or for an earlier or later age of developing Parkinson disease, comprising detecting the presence of a genetic marker associated with Parkinson disease.